Coinfections with hepatitis B virus (HBV) and HIV are very frequent. Although HBV is a DNA virus, it replicates via reverse transcription like HIV. Structural similarities between the enzymatic pocket of the HBV DNA polymerase and HIV-1 reverse transcriptase are the basis that certain drugs inhibit both enzymes and thus the replication of both viruses. HBV components increase the pathogenic action of HIV and vice versa directly by certain proteins like HBsAg in the case of HBV and HIV-encoded Tat and Vpr and by disturbing the cytokine balance in affected cells. Antiretroviral therapy is highly beneficial for HIV/HBV-coinfected patients, but carries the risk of drug-induced resistance development and hepatotoxicity. Even with restoration of the immune capacity, signs of hepatic inflammation may develop even after 10 years of treatment.

Keywords:
HIV/hepatitis B virus coinfection, Pathogenesis, Antiretroviral therapy
1.
Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
2.
Hu WS, Hughes SH: HIV-1 reverse transcription. Cold Spring Harb Perspect Med 2012;2:a006882.
3.
Le Grice SF: Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J Biol Chem 2012;287:40850-40857.
4.
Arts EJ, Hazuda DJ: HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2012;2:a007161.
5.
Poch O, Sauvaget I, Delarue M, Tordo N: Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989;8:3867-3874.
6.
Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E: Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001;75:4771-4779.
7.
Ghany M, Liang TJ: Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterol 2007;132:1574-1585.
8.
Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF: Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-757.
9.
Levy JA: HIV and the Pathogenesis of AIDS, ed 3. Washington, ASM Press, 2007.
10.
Mallet V, Vallet-Pichard A, Pol S: The impact of human immunodeficiency virus on viral hepatitis. Liver Int 2011;31(suppl 1):135-139.
11.
Herbein G, Gras G, Khan KA, Abbas W: Macrophage signaling in HIV-1 infection. Retrovirology 2010;7:34.
12.
Azurmanyan A, Reis HMGP, Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013;13:123-135.
13.
Yu Y, Gong R, Mu X, Chen Y, Zhu C, Sun Z, Chen M, Lin Y, Zhu Y, Wu J: Hepatitis B virus induces a novel inflammation network involving three inflammatory factors, IL-29, IL-8, and cycloxygenase 2. J Immunol 2011;187:4844-4860.
14.
Foster JL, Denial SJ, Temple BR, Garcia JV: Mechanism of HIV-1 Nef function and intracellular signaling. J Neuroimmune Pharmacol 2011;6:230-246.
15.
Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robertson DL, Rozanov MN, Katz KS, Maglott DR, Pruitt KD, Dieffenbach CW: Cataloguing the HIV type 1 human protein interaction network. AIDS Res Hum Retroviruses 2008;24:1497-1502.
16.
Rehermann B: Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-868.
17.
Chang J, Block TM, Guo JT: The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy. Antiviral Res 2012;96:405-413.
18.
Mu Y, Yu Y, Yue X, Musarat I, Gong R, Zhu C, Liu Y, Liu F, Zhu Y, Wu J: The x protein of HBV induces HIV-1 long terminal repeat transcription by enhancing the binding of C/EBPβ and CREB1/2 regulatory proteins to the long terminal repeat of HIV-1. Virus Res 2011;156:81-90.
19.
Li YJ, Wang HL, Li TS: Hepatitis B virus/human immunodeficiency virus coinfection: interaction among human immunodeficiency virus infection, chronic hepatitis B infection, and host immunity. Chin Med J 2012;125:2371-2377.
20.
Zoutendijk R, Zaajer HL, de Vries-Sluijs TEMS, Reijnders JGP, Mulder JW, Kroon FP, Richter C, van der Eijk AA, Sonneveld MJ, Hansen BE, de Man RA, van der Ende ME, Janssen HLA: Hepatitis B surface antigen decline and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 2012;206:974-980.
21.
Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Troittier B, Tsarevsky I, Villeneuve JP: Management and treatment of hepatitis B virus in patients with HIV infection: a practical guide for health care professionals: Can J Infect Dis Med Microbiol 2011;22:88-96.
22.
Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Nuňez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R: Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One 2013;8:e68152.
23.
Lada O, Gervais A, Branger M, Peytavin G, Roquebert B, Collin G, Fraquiero G, Moucari R, Hamet G, Martinot-Peignoux M, Matheron S, Marcellin P: Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver Int 2012;32:93-101.
24.
Laprise C, Baril JG, Dufresne S, Trottier H: Association between tenofovir exposure and reduced kidney function in a cohort of HIV positive patients: results from 10 years of follow-up. Clin Infect Dis 2013;56:567-575.
25.
Anderson AM, Mosunjac MB, Palmore MP, Osborn MK, Muir AJ: Development of fatal acute liver failure in HIV-HBV coinfected patients. World J Gastroenterol 2010;16:4107-4111.
26.
Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML: Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012;205:185-193.
27.
Seeger C, Mason WS: Sodium-dependent taurocholic cotransporting polypeptide: a candidate receptor for human hepatitis B virus. Gut 2013;62:1093-1095.
28.
Shugarts S, Benet LZ: The role of transporters in the pharmacokinetics of orally administered drugs. Pharmaceut Res 2009;26:2039-2054.
29.
Kosi L, Reiberger T, Payer BA, Grabmeier-Pfistershammer K, Strassl R, Rieger A, Peck-Radosavljevic M: Five-year on-treatment efficacy of lamivudine-tenofovir and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat 2012;19:801-810.
30.
Wang S, Chen Z, Hu C, Qian F, Cheng Y, Wu M, Shi B, Chen J, Hu Y, Yuan Z: Hepatitis B surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013;190:5142-5151.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.